Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24323854 | 0.91 | NPC1 (0.60) | POLBRAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL24322694 | 0.88 | SMN1; SMN2 (0.49) | RAB9ANPC1SMN1; SMN2KMT2AHPGD | |
| SCHEMBL24322763 | 0.83 | KMT2A (0.44) | SMN1; SMN2TDP1KMT2AHPGDALDH1A1 | |
| SCHEMBL23022845 | 0.81 | POLB (0.59) | POLBTDP1KMT2A | |
| SCHEMBL28351992 | 0.77 | POLB (0.51) | POLBRAB9ANPC1HPGDEPHX1 | |
| SCHEMBL24322891 | 0.76 | NPC1 (0.58) | POLBRAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL3289066 | 0.76 | ACHE (0.52) | RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL28747806 | 0.76 | FDPS (0.45) | POLBSMN1; SMN2KMT2AALDH1A1HTR2B | |
| SCHEMBL24323552 | 0.75 | SMN1; SMN2 (0.51) | RAB9ANPC1SMN1; SMN2KMT2AEPHX1 | |
| SCHEMBL24322789 | 0.75 | SMN1; SMN2 (0.48) | RAB9ANPC1SMN1; SMN2KMT2AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | POLB 4461/4885RAB9A 435/4885NPC1 2900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.